Stable analog of pifithrin-α (Prod. No. BML-GR325), with biological properties similar to its parent compound, but with reduced cytotoxicity. Inhibitor of p53. Reversibly inhibits p53-dependent transactivation of p53-responsive genes and reversibly blocks p53-mediated apoptosis. Potent STAT6 transcriptional inhibitor. Increases apoptosis in target cells when used in combination with antimicrotubule agents.
Product Details
| Formula: | C16H16N2S . HBr |
| |
| MW: | 268.4 . 80.9 |
| |
| CAS: | 60477-34-1 |
| |
| Purity: | ≥95% (HPLC, TLC) |
| |
| Appearance: | White to off-white powder. |
| |
| Solubility: | Soluble in DMSO (100mg/ml). |
| |
| Shipping: | Ambient Temperature |
| |
| Long Term Storage: | -20°C |
| |
| Handling: | Protect from light and moisture. Keep under inert gas. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Pifithrin-alpha inhibits p53 signaling after interaction of the tumor suppressor protein with hsp90 and its nuclear translocation: P.J. Murphy, et al.; J Biol Chem
279, 30195 (2004),
Abstract;
Suppression of p53: a new approach to overcome side effects of antitumor therapy: E.A. Komarova, et al.; Biochemistry
65, 41 (2000),
Abstract;
Full Text
A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy: P.G. Komarov, et al.; Science
285, 1733 (1999),
Abstract;
Cancer research. A new way to combat therapy side effects: D. Ferber; Science
285, 1651 (1999),
Abstract;
Related Products
